The Flowflex SARS‐CoV‐2 Antigen Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of the nucleocapsid protein antigen from SARS‐CoV‐2 in nasal and nasopharyngeal swab specimens directly from individuals who are suspected of COVID‐19 by their healthcare provider within the first seven days of the onset of symptoms.
The Flowflex SARS‐CoV‐2 Antigen Rapid Test does not differentiate between SARS‐CoV and SARS‐CoV‐2. Results are for the identification of SARS‐CoV‐2 nucleocapsid antigen. This antigen is generally detectable in upper respiratory samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co‐infection with other viruses.
The agent detected may not be the definite cause of disease. Negative results from patients with more than seven days post symptom onset should be treated as presumptive and confirmed with a molecular assay, if necessary, for patient management. Negative results do not rule out SARS‐CoV‐2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID‐19.
- Box includes 1 x individual test
- Cassette Format
- Detects the nucleocapsid protein antigen from SARS-CoV-2
- Nasal Specimen sample Results in 15 minutes
- Relative Sensitivity: 97.1% (83.8%-99.9%)
- Relative Specificity: 99.6% (97.7%-99.9%)
- Accuracy: 99.3% (97.5%-99.9%)